Zimmer Biomet (NYSE:ZBH) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

07 Nov 2026, 17:03 by Sarita Garza · The Markets Daily

Zimmer Biomet (NYSE:ZBH – Get Free Report) had its target price lifted by Royal Bank Of Canada from $110.00 to $125.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical equipment provider’s stock. Royal Bank Of Canada‘s target price suggests a potential upside of 18.55% from the company’s current price.

A number of other brokerages also recently issued reports on ZBH. Robert W. Baird set a $104.00 price target on Zimmer Biomet in a report on Thursday, August 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Sanford C. Bernstein lifted their target price on Zimmer Biomet from $93.00 to $107.00 and gave the company a “market perform” rating in a research note on Thursday. Truist Financial boosted their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Finally, Barclays raised shares of Zimmer Biomet to a “hold” rating in a research report on Wednesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $111.95.

Read Our Latest Research Report on ZBH

Zimmer Biomet Stock Down 1.3%

Shares of ZBH traded down $1.41 during mid-day trading on Thursday, hitting $105.44. The company’s stock had a trading volume of 2,660,421 shares, compared to its average volume of 2,021,390. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The company’s 50-day moving average is $95.13 and its 200-day moving average is $92.08. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $112.54. The firm has a market capitalization of $20.11 billion, a price-to-earnings ratio of 26.69, a PEG ratio of 2.34 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. Zimmer Biomet’s revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company posted $1.90 earnings per share. On average, equities research analysts forecast that Zimmer Biomet will post 8.55 EPS for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Chad F. Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by insiders.

Institutional Trading of Zimmer Biomet

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Zimmer Biomet during the 2nd quarter valued at approximately $1,344,282,000. State Street Corp lifted its stake in shares of Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after buying an additional 52,044 shares during the period. Primecap Management Co. CA purchased a new stake in shares of Zimmer Biomet during the second quarter valued at $328,578,000. Dimensional Fund Advisors LP grew its holdings in shares of Zimmer Biomet by 1.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after buying an additional 24,208 shares during the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Zimmer Biomet during the second quarter valued at $187,480,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

Positive Sentiment: Q3 results beat expectations. Zimmer Biomet reported adjusted EPS of $1.90 versus the $1.88 consensus and revenue of $2.06 billion versus $2.04 billion expected. Revenue increased 3.1% year over year, providing a fundamental tailwind. Third-quarter earnings results
Positive Sentiment: Analysts raised price targets. UBS lifted its target to $130 and kept a Buy rating; RBC raised its target to $125 and maintained Outperform. JPMorgan, Citi, Wells Fargo, and Bernstein also increased targets, though their ratings are neutral or equivalent. The revisions suggest improved expectations, but analyst conviction is mixed. UBS rating and target RBC rating and target
Positive Sentiment: New surgical technology initiative. The company introduced “surgeon-guided autonomy,” a closed-loop framework called “Predict. Perform. Recover.” It could support Zimmer Biomet’s longer-term competitive positioning, though the announcement did not provide a near-term financial impact. Surgeon-guided autonomy announcement
Neutral Sentiment: Shares recently reached a one-year high after the earnings beat. That reflects positive momentum, but could also leave the stock susceptible to consolidation. The available reports do not point to a specific new negative fundamental catalyst. Zimmer Biomet reaches one-year high

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.